Bristol Myers Squibb leads $237M investment in AI drug development startup Pathos AI
US-based AI drug development startup Pathos AI has closed a $237 million Series E funding round at a valuation of approximately $3 billion. The round was led by pharmaceutical giant Bristol Myers Squibb, with participation from other existing investors.
US-based AI drug development startup Pathos AI announced on October 23, 2026, that it has closed a $237 million Series E funding round at a post-money valuation of approximately $3 billion. The round was led by pharmaceutical giant Bristol Myers Squibb, with participation from other existing investors.
Pathos AI is developing an artificial intelligence platform called Foundry, which uses thousands of specialized AI agents to aggregate clinical data, genomics and competitive landscape information in real time to identify promising drug molecules and plan clinical trials. The company stated that the new capital will primarily finance its key priority, the JSKN016 cancer therapy program, along with three other drug initiatives.
The investment is part of a broader strategic collaboration between Pathos AI, Bristol Myers Squibb, and Tempus AI. Under the agreement, Pathos AI will pay Tempus AI $55 million over five years to license anonymized patient data related to neurological conditions. This data will be analyzed using Foundry to help Bristol Myers Squibb improve its clinical trial designs and patient identification.